Showing 3301-3310 of 7015 results for "".
Contact Lens Success in Modern Optometric Clinics
https://reachmd.com/programs/empower/contact-lens-success-in-modern-optometric-clinics/49028/Daily contact lens patients live their best lives when providers match their anatomy and needs to the lens that fits them best.Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
https://reachmd.com/programs/project-oncology/concurrent-atezolizumab-fails-to-improve-survival-in-limited-stage-sclc/56338/JAK Inhibitors in Psoriatic Arthritis: Reassessing Safety in the Real World
https://reachmd.com/programs/living-rheum/jak-inhibitors-psoriatic-arthritis-safety-real-world/56344/Early ALS Patients Show Slowed Decline with Pridopidine Treatment
https://reachmd.com/programs/clinicians-roundtable/early-als-patients-show-slowed-decline-with-pridopidine-treatment/54640/Exploring the Future of Psoriasis Treatment with Oral Agents
https://reachmd.com/programs/dermconsult/future-psoriasis-treatment-oral-agents/39685/Novel oral therapies are expanding the possibilities for personalized care in psoriasis, offering biologic-like efficacy with greater flexibility. Join Dr. Christopher Bunick as he discusses the evolving role of oral agents in the future of psoriasis treatment and the importance of real-world data iEarly Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
https://reachmd.com/programs/project-oncology/early-adulthood-weight-breast-tissue-complexity/48767/Reimagining the Aesthetic Surgery Experience
https://reachmd.com/topics/practice-development/reimagining-the-aesthetic-surgery-experience/49013/How Greenwich Street Surgical came to lifeBeyond Fulvestrant: Oral SERDs Redefining ER Targeting
https://reachmd.com/programs/cme/beyond-fulvestrant-oral-serds-redefining-er-targeting/39800/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
https://reachmd.com/clinical-practice/oncology-hematology/amivantamab-monotherapy-or-in-combination-with-paclitaxel-in-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-origami-4-study-results/39780/In the phase 1b/2 OrigAMI-4 trial, amivantamab alone or with paclitaxel showed strong and durable responses in previously treated recurrent or metastatic HNSCC.mRNA-1283 and the Future of COVID-19 Vaccination Strategies
https://reachmd.com/programs/clinicians-roundtable/mrna-1283-and-the-future-of-covid-19-vaccination-strategies/36421/While the mRNA-1283 COVID-19 vaccine shows comparable safety and immune response to its predecessor, mRNA-1273, its true clinical advantage remains under investigation, and depends in part on its integration into wider vaccination plans. Learn how this evolving vaccine technology may influence futur